difference in those below and above 80 years in terms of mortality in relation to the nature of access? A recent report of vascular access in Octagenarians questioned the wisdom of fistula first in those over 80 arguing that outcomes are comparable in the very old between AVF and AVG, but still superior to catheters [2, 3] .
difference in those below and above 80 years in terms of mortality in relation to the nature of access? A recent report of vascular access in Octagenarians questioned the wisdom of fistula first in those over 80 arguing that outcomes are comparable in the very old between AVF and AVG, but still superior to catheters [2, 3] .
Have the authors examined the timing of the presentations of these patients in relation to the initiation of RRT? As one would expect late presenters, with known worse survival, to be those who were also started with a CVC.
In view of the short life expectancy in older HD patients with co-morbidities, would the author comment on cost-benefit analysis of catheter first, this in spite of the observed and expected marginal increase in relative risk of death in this age group?
Ultimately, a patient-centred approach that does not deny older HD patients adequate access with a mimimum associated risk is advisable regardless of the nature of the vascular access. While AVF is, by far, the treatment of choice in the great majority, a CVC may be a useful option in older patients with significant underlying co-morbidities and atherosclerosis, where a high primary and secondary failure rate of native access (AVF) is often an added burden that may contribute to their increased morbidity, hospitalization rates and mortality. and high parathyroid hormone (PTH) levels (n = 50; 49%) received oral cholecalciferol (666 IU/day), whereas those without hyperparathyroidism (n = 51; 51%), independent of their vitamin D status, did not receive any cholecalciferol, and were considered as the control group.
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Results. Cholecalciferol administration led to a rise in mean 25 (OH)D levels by 53.0 ± 41.6% (P < 0.001). Urinary albumin-tocreatinine ratio (uACR) decreased from (geometric mean with 95% confidence interval) 284 (189-425) to 167 mg/g (105-266) at 6 months (P < 0.001) in the cholecalciferol group, and there was no change in the control group. Reduction in a uACR was observed in the absence of significant changes in other factors, which could affect proteinuria, like weight, blood pressure (BP) levels or antihypertensive treatment. Six-month changes in 25 (OH)D levels were significantly and inversely associated with that in the uACR (Pearson's R = −0.519; P = 0.036), after adjustment by age, sex, body mass index, BP, glomerular filtration rate and antiproteinuric treatment. The mean PTH decreased by −13.8 ± 20.3% (P = 0.039) only in treated patients, with a mild rise in phosphate and calcium-phosphate product [7. 0 ± 14.7% (P = 0.002) and 7.2 ± 15.2% (P = 0.003), respectively].
Conclusions. In addition to improving hyperparathyroidism, vitamin D supplementation with daily cholecalciferol had a beneficial effect in decreasing albuminuria with potential effects on delaying the progression of CKD.
I N T R O D U C T I O N
Patients with chronic kidney disease (CKD) are at increased risk for cardiovascular disease and death. These relative risks for adverse outcomes increase as levels of albuminuria rise, even at levels of microalbuminuria (30-299 mg/g) [1, 2] . Therefore, albuminuria is not only a unequivocal surrogate marker for kidney progression and future cardiovascular events, but its reduction is also a treatment goal [3, 4] . Unfortunately, the current therapies for lowering albuminuria, focused on controlling salt intake, weight, blood glucose and blood pressure (BP) with a preferential use of renin-angiotensin-aldosterone system (RAAS) inhibitors, are unable to completely block the progression of renal disease. Hence, new treatment strategies are required [5] . Vitamin D deficiency is highly prevalent in patients with CKD even in the early stages [6] [7] [8] [9] [10] [11] . In several observational studies, vitamin D deficiency is related to albuminuria, lower glomerular filtration rate (GFR) and CKD progression [6, 8, [12] [13] [14] [15] , as well as to an increased risk of left ventricular hypertrophy, arterial calcification and mortality [15] [16] [17] [18] . Growing evidence supports a potential role for vitamin D receptor (VDR) activation in reducing proteinuria. Randomized clinical trials using active vitamin D analogues ( paricalcitol) have shown reduction in proteinuria among CKD patients [19] [20] [21] [22] . It is plausible that potential antiproteinuric benefits might exist with vitamin D supplementation. However, the antiproteinuric effect of nutritional vitamin D supplementation has been described in only one uncontrolled study [23] .
Beyond these pleiotropic extraskeletal effects, prospective studies in non-dialysis CKD patients have shown that restoration of adequate vitamin D status with cholecalciferol can increase calcitriol levels and to some extent control parathyroid hormone (PTH) levels [24] [25] [26] [27] [28] [29] [30] [31] .
As a result of these findings, guidelines on the management of CKD-related bone and mineral disorders suggest that hypovitaminosis D should be corrected [32, 33] . The limited data behind these recommendations and our awareness of the therapeutic power of vitamin D supplementation to reduce proteinuria encouraged us to conduct a controlled study to investigate the impact of vitamin D supplementation in CKD patients with vitamin D deficiency. The aim of our study was to evaluate whether vitamin D supplementation with daily cholecalciferol could reduce albuminuria in CKD patients.
M AT E R I A L S A N D M E T H O D S
Study design
This single-centre, controlled, open-label prospective intervention study tested the hypothesis that vitamin D supplementation with daily cholecalciferol may have an antiproteinuric effect in patients with CKD Stages 3-4. Patients were recruited from our outpatient clinics from January 2009 to 2012. Inclusion criteria were age ≥18 years and CKD Stages 3-4 according to the Modification of Diet in Renal Disease (MDRD) formula [34] , with persistent albuminuria, defined as urinary albumin-to-creatinine ratio (uACR) of >30 mg/g in at least two consecutive spot urine samples. Exclusion criteria were CKD Stages 1-2 or 5; uACR of <30 mg/g; significant liver disease; malabsorption and previous treatment with phosphate binders and other vitamin D preparations (including calcitriol or paricalcitol). In accordance with the treatment protocol, the use of these drugs was contraindicated during the whole study period, in order to show the isolated effect of cholecalciferol on bone metabolism markers.
The Dr Peset Hospital Research Ethics Committee approved this study and all patients signed consent forms, consistent with the Declaration of Helsinki. [35] . Because of concerns for calcium and phosphate overload, the dosing of vitamin D administered (666 IU daily in the form of 10 drops, from Berenguer Laboratories, Spain) was moderate, in accordance with the current nutritional recommendations (600-800 IU/day) [36, 37] . Patients were regularly followed in the renal clinic. During the 6-month follow-up, antihypertensive treatment could be adjusted if necessary. The target for BP was ≤130/80 mmHg. No restriction on dietary salt or protein was implemented.
Intervention
Laboratory tests
Blood samples were collected at baseline and at 6-month follow-up. Primary end points were the changes in serum levels of 25(OH)D and uACR under vitamin D repletion using cholecalciferol. Additionally, end points were changes in other laboratory and clinical parameters, including PTH, serum calcium corrected for albumin, phosphorous and calciumphosphate product (CaxP), estimated GFR (eGFR), C-reactive protein (CRP), haemoglobin, BP, weight and use of antihypertensive drugs. 25(OH)D and PTH levels were assessed by an electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics GmbH, Germany). Vitamin D deficiency and insufficiency were defined by the 25(OH)D level of <15 and 15-29 ng/mL, respectively [35] . It was reported the time of year with more or less sunlight in which the samples were collected. Total serum calcium and phosphate were measured by colorimetric assay (Roche Diagnostics GmbH, Germany).
Statistics
The aim of this study was to determine the effect of cholecalciferol on albuminuria. As there were no published controlled trials, we calculated that a sample size of 50 patients per arm was needed for 80% power to detect a difference in logtransformed uACR of -0.255 mg/g [standard deviation (SD) 0.45] from baseline to 6-month measurement between cholecalciferol and control group with two-sided significance level of 0.05. The expected reduction in an uACR was based on our own clinical setting.
Results are expressed as mean and SD for continuous variables with normal distribution. Skewed variables were logtransformed for the statistical analyses, and the result was expressed exponentially to show the results in the original unit of measurement (geometric mean with 95% confidence interval). Categorical variables were reported as frequency. Paired t-test was used to compare changes from baseline to the end of study in each arm. Differences in absolute laboratory results between groups at baseline and at the end of study were also compared by two-sample t-tests or Pearson χ 2 for continuous and categorical variables, respectively. Relationships between parameters were measured using Pearson's correlation coefficient. A value of P < 0.05 was considered statistically significant. Analyses were performed using SPSS 15.0.
R E S U LT S
Baseline data
The patient disposition is summarized in Figure 1 . One hundred and one patients were included in the final analysis. Sixty-four (63%) were men, mean age was 72.3 ± 13.0 (range, 23.0-90.8) years, 50 received cholecalciferol and 51 were assigned to the control group. The baseline characteristics by the treatment group are summarized in Tables 1 and 2 . At baseline, patients in the cholecalciferol group had higher PTH and lower 25(OH)D levels, with a higher proportion of patients with CKD Stage 4. Mean age was also higher in the cholecalciferol group. No other significant differences were observed at baseline. The same proportion of patients in both groups were enrolled during the summer and winter seasons [cholecalciferol group: 22 (44%) and control group: 29 (57%); P = 0.137].
25(OH)Dlevels
A significant increase in mean 25(OH)D levels was observed in the cholecalciferol group, whereas the opposite evolution was observed in the control group (Table 3 and Figure 2a ). The 25(OH)D increased by 53.0 ± 41.6% (P < 0.001) in the cholecalciferol group and decreased by 9.0 ± 26.7% (P = 0.037) in the control group (P < 0.001 between groups). The number of patients with optimal levels of 25(OH)D increases only in the cholecalciferol group.
Albuminuria and BP A significant reduction in uACR levels was observed only in the cholecalciferol group (Table 4 and Figure 3a ). Cholecalciferol administration reduced the uACR by −53.2% (−66.0 to −27.0%), whereas there was an increase of 7.1% (−25.3 to 53.3%) in the control group (P = 0.005 between groups). Only cholecalciferol group showed a significant trend towards restoration of normoalbuminuria. Reduction in the uACR was observed in the absence of significant changes in other factors, which could affect proteinuria, like weight, BP or antihypertensive treatment (Table 4) . Similar findings were obtained in the subgroup of patients with baseline macroalbuminuria [n = 42; baseline mean uACR: 959 mg/g (763-1206); Table 5] , showing a significant decrease in the uACR only in the treatment group [−53.2% (−67.6 to −32.3%) versus −3.0% (−41.0 to 59.5%); P = 0.016].
F I G U R E 1 : Flow diagram of patient recruitment and follow-up. Subjects with CKD (n = 265) were screened for participation in the study. One hundred and one patients were assigned to receive cholecalciferol or to be observed according to their PTH baseline levels, completed the 6-month study and were included in the final analysis. 
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As the antihypertensive medications were modified in 32 patients in order to achieve a tight BP control, we analysed the uACR modifications in the subgroup of patients without changes in class or dosing of antihypertensive treatment throughout the study (n = 69). The uACR decreased from 304 (185-501) to 204 mg/g (119-355; P = 0.004) in the cholecalciferol group (n = 36), whereas uACR remained unchanged [214 (139-328) versus 218 mg/g (113-419); P = 0.621] in the control group (n = 33; Figure 3b ). Cholecalciferol administration reduced the uACR by −36.6% (−52.8 to −14.8%; P = 0.004), whereas there was an increase of 9.6% (−25.9 to 40.1%; P = 0.621) in the control group (P = 0.022 between groups). BP remained unchanged in this subgroup of patients.
CKD progression and other laboratory parameters A non-significant decrease in eGFR was observed in both the cholecalciferol (−1.6 ± 7.9 mL/min/1.73 m 2 ; P = 0.173) and 
O R I G I N A L A R T I C L E
P. Molina et al.
102
the control group (−1.6 ± 8.3 mL/min/1.73m 2 ; P = 0.177), without differences between groups (P = 0.985). CRP and haemoglobin levels did not change throughout the study (Table 4) .
Relationships between vitamin D concentration and albuminuria
Significant correlation analyses of serum 25(OH)D with uACR at baseline and at 6-month follow-up are shown in Figure 4a and b, respectively. Multiple linear regression analysis of 6-month demonstrated that changes in 25(OH)D were significantly and inversely associated with that in the uACR (Pearson's R = −0.519; P = 0.036), after adjustment by age, sex, body mass index, BP, GFR and antiproteinuric treatment.
Markers of bone mineral metabolism
A significant reduction in mean PTH levels was observed in the cholecalciferol group, whereas the opposite evolution was observed in the control group (Table 3 and Figure 2b ). PTH decreased by −13.8 ± 20.3% (P = 0.039) in the treated patients and increased by 24.4 ± 45.3% (P = 0.001) in the control group (P < 0.001 between groups). Cholecalciferol administration succeeded in controlling PTH levels in 22 (44%) of the treated 
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C h o l e c a l c i f e r o l a n d a l b u m i n u r i a patients (P < 0.001), whereas 15 (29%) patients in the control group developed hyperparathyroidism (P < 0.001). There was a significant rise in phosphate and CaxP in the cholecalciferoltreated patients [7.0 ± 14.7% (P = 0.002) and 7.2 ± 15.2% (P = 0.003), respectively], but not in the control group [6.3 ± 17.5% (P = 0.069) and 6.3 ± 18.3% (P = 0.101), respectively]. These differences between groups did not reach significance (P = 0.839 and 0.793, respectively). In both groups, calcium levels remained unchanged over time.
Relationships between vitamin D concentration and markers of bone mineral metabolism
Multiple linear regression analyses of 6 months demonstrated that changes in 25(OH)D were significantly and inversely associated with that in PTH (Pearson's R = −0.362; P = 0.010) after adjustment by age, sex, GFR, calcium and phosphate levels. No correlations were observed between changes in 25(OH)D, corrected calcium and phosphate levels.
D I S C U S S I O N
The present controlled study quantifies the response of albuminuria and bone metabolism parameters to nutritional vitamin D supplementation with daily cholecalciferol in proteinuric CKD patients with SHPT and inadequate vitamin D stores. Although there are some clinical trials examining the effect of VDR activation with paricalcitol on albuminuria [19] [20] [21] [22] , this is the first controlled study, to our knowledge, reporting albuminuria as the primary outcome and showing the antiproteinuric effect of vitamin D repletion using cholecalciferol.
The analysis at baseline of all the patients showed a weak inverse but significant correlation between 25(OH)D and uACR. This association is not new and has been reported in previous cross-sectional studies [6, 12, 14, 38] . More interestingly, in our study, changes in 25(OH)D after cholecalciferol treatment are inversely associated with that in the uACR, supporting the hypothesis about the antiproteinuric effect of VDR activation.
This antiproteinuric effect of nutritional vitamin D repletion is novel given that it has been previously reported only in one uncontrolled study [23] , so that none of the current guidelines for the management of CKD patients, including the most recently published, refers to the activation of VDR as a target for renal protection [39] [40] [41] . Kim et al. [23] observed a significant reduction in the uACR in 49 CKD patients with Type 2 diabetic nephropathy after treatment with oral cholecalciferol. In contrast, other interventional studies with vitamin D supplementation did not demonstrate this antiproteinuric effect, although in all of them the changes in proteinuria did not constitute a primary end point, and the number of patients where the proteinuria was analysed was small [25] [26] [27] [28] .
In this study, cholecalciferol administration reduced the uACR by −53%. Although baseline mean levels of the uACR were <500 mg/g, we think that the reduction of albuminuria observed could be clinically relevant, given that individuals with proteinuria, even at levels of microalbuminuria, have a significantly increased risk for CKD progression and all-cause and cardiovascular mortality compared with those who have a lower uACR [1, 2, [42] [43] [44] , and changes in albuminuria predict mortality and morbidity [3, 45] . Although the study was not designed to demonstrate an antiproteinuric effect in patients with a greater degree of proteinuria, we observed similar findings in the subgroup of patients with severely increased albuminuria. This reduction is even more marked than those achieved in relevant trials with the same 6-month follow-up primary end point. In the VITAL study [19] , 2 µg/day of paricalcitol reduced the uACR by 30%, from a baseline uACR of 745 mg/g. In the AVOID study [46] , 300 mg of aliskiren was associated with a reduction in the uACR of 20%, from a baseline uACR of 513 mg/g.
Whether the decrease in the uACR after cholecalciferol supplementation could be translated into a lower rate of progression of proteinuric CKD patients cannot answered with our study, given that it was not the objective for which the study was designed and its 6-month follow-up did not allow time for testing it. Nevertheless, experimental studies with VDR activation have demonstrated an ability to delay the progression of renal disease [47] . In humans, data from previous randomized clinical trials in proteinuric CKD patients showed that albuminuria reduction was associated with better renal outcomes in CKD patients [42] [43] [44] . In the RENAAL study, patients with less residual albuminuria experienced fewer renal events and a lower probability of starting on dialysis [3] . In the same study, the group of patients with a greater F I G U R E 3 : Evolution of the uACR at a 6-month follow-up (a) in the study group (n = 101) and (b) in the subgroup of patients (n = 69) who had no changes of antihypertensive medication.
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antialbuminuric response from baseline to 6 months (albuminuria reduction ≥30%) had less renal events during the follow-up [4] . Taking all these data together, we agree with the Kidney Disease: Improving Global Outcomes (KDIGO) recommendation to consider the threshold value for abnormally elevated uACR of 30 mg/g or higher, and we speculate that the antiproteinuric effect observed after VDR activation could translate into a better renal outcome.
The major target of vitamin D therapy in CKD is the management of SHPT. In this setting, the use of nutritional vitamin D supplementation has not been considered much because of the lack of renal 1-α-hydroxylation activity. However, vitamin D deficiency could contribute to SHPT and KDIGO guidelines recommend supplementing before treatment with active vitamin D [32] . Our study accurately tests this approach. Only patients with high PTH and low 25(OH) D levels received cholecalciferol, showing a modest but significant decline in PTH levels after cholecalciferol administration. Similar findings have been reported in several trials [25, 26, 28, [48] [49] [50] [51] [52] . A meta-analysis performed by Kandula et al. [29] revealed a net reduction of −26 pg/mL in PTH levels after vitamin D supplementation, whereas the PTH decreased by Table 5 . Baseline and final non-mineral-related end points with simultaneous antihypertensive treatments in patients with severely increased albuminuria (baseline ACR of 300 mg/g or higher) 
C h o l e c a l c i f e r o l a n d a l b u m i n u r i a −21 pg/mL (−13.8% from baseline) in our treated patients. Noteworthy is that this reduction is lower than the decrease observed after active vitamin D analogue treatment (−49 pg/ mL) [53] , especially with paricalcitol, which can reach to −120 pg/mL (−45.2% from baseline) among CKD patients not on dialysis [54] . Whether the benefit of native vitamin D would be synergistic to that obtained with active vitamin D remains unclear. The improvement in SHPT was achieved in spite of the mean vitamin D concentration at the end of the study did not reach the optimal recommended levels. This might be due to the moderate dose of vitamin D (666 IU/day) administered in our study. Studies supplementing with the equivalent of 700-1000 IU/day showed similar results [27, 41, 42] , suggesting that daily doses of vitamin D >2000 IU could be required to achieve optimal vitamin D status [30] . Nevertheless, before recommending a higher vitamin D intake, the potential benefits of increasing cholecalciferol dose should be balanced against the risk of calcium and phosphate overload reported in several studies where high doses were employed [26, 28, 51] . In this regard, our study, with no confounding effects of the phosphate binders, showed a significant rise in phosphate and CaxP levels in the cholecalciferol-treated patients. Oksa et al. [49] found that 20 000 IU cholecalciferol per week (∼2857 IU/ day), but not 5000 IU per week (∼714 IU/day), increased urine calcium excretion. All these data support the moderate dosing of vitamin D administered in our study, which is in accordance with the current nutritional recommendations [36, 37] .
Our analysis revealed a worsening in mineral-related end points in the control group, with a significant decline in serum 25(OH)D and an increase in PTH levels. These data support the hypothesis that correcting 25(OH)D deficiency prior to elevations in serum PTH could delay the onset of SHPT. A recent trial has found that ergocalciferol prevents SHPT in children with an early CKD stage [55] . These results suggest that current guidelines could be limited, because they recommend the treatment of SHPT as opposed to prevention.
Strengths and limitations
The strengths of this study are its prospective, controlled design, reporting albuminuria as the primary outcome, and the absence of confounding factors in the assessment of the effect of cholecalciferol in both renal and mineral-related parameters. The novel antiproteinuric effect observed cannot be explained by any changes in the class or dosing of antihypertensive medications throughout the study, including RAAS inhibition. The reduction in the uACR was also consistent in the subgroup of patients with severely increased baseline albuminuria or who had no changes of antihypertensive drugs. Although there are some randomized controlled trials showing the effect of cholecalciferol on mineral-related parameters [25-28, 31, 48-52, 56] , to our knowledge, this is the first controlled study to show the isolated effect of cholecalciferol, given that the use of phosphate binders and vitamin D analogues were contraindicated. As the enrollment of the patients was undertaken in same proportion during the summertime and wintertime in both groups, the natural seasonal changes in 25(OH)D levels cannot affect the results.
There are limitations to our study to be discussed. The study was un-randomized. The patients selected for the study had heterogeneous causes of CKD, and there were differences between groups at baseline in PTH levels and consistently, in 25(OH)D, eGFR levels and age. All of these differences were expected because the study design was based on K-DOQI guidelines. The fact that only patients with SHPT were treated, iPTH level increases as renal function and vitamin D level deteriorates and eGFR decreases with age, explains the differences observed between groups at baseline. Although we think it gave a valuable practical clinical sense to the study results, we were not able to answer the question whether the cholecalciferol treatment would have similar effects on proteinuria in patients with sufficient serum 25(OH)D levels or without SHPT. Although 6-month follow-up seems enough to detect changes in proteinuria [19, 46] , this period of intervention was not long enough to detect differences in the progression of renal disease between groups or to prove whether the antiproteinuric effect will be sustained in the long term. It would have been interesting to study changes in additional bone-related markers such as FGF-23, calciuria or phosphaturia to help to balance the risk-benefit of vitamin D supplementation and to assess the urinary sodium excretion, which might play a key role in the changes of proteinuria observed. Future studies may explore these effects.
Conclusion and clinical implications
The current controlled study suggests that vitamin D repletion with daily mild doses of cholecalciferol may be effective to reduce albuminuria in patients with CKD 3-4 stages, with potential long-term benefits for this population that should be tested in future vitamin D supplementation trials. The reduction of proteinuria and PTH levels in proteinuric CKD patients with low vitamin D status and SHPT suggests that vitamin D repletion should be considered the first therapeutic approach in these patients, and this treatment should precede the use of active metabolites. Furthermore, our results support not only current recommendations about vitamin D repletion after the diagnosis of SHPT, but also emphasize the early treatment of vitamin D deficiency to prevent the rise in PTH levels. All of these benefits could be obtained without achieving suggested optimal vitamin D status, whereas higher doses of cholecalciferol can lead to a calcium and phosphate overload, highlighting the need for a revision of the current guidelines. Future vitamin D supplementation trials in non-dialysis CKD are warranted to study strategies for improving vitamin D status, as well as improving relevant clinical outcomes, as fracture risk, renal progression, cardiovascular disease and mortality.
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